Clear, engaging, and practical updates on clinical psychiatry.

Subscribe for free on Apple Podcasts, Android, or Stitcher. Let us know what you think and suggest topics by taking the Podcast Survey.


Cognitive Enhancers: The Brain on Chess

January 11, 2021 | Podcasts

The Queen’s Gambit is Netflix’s critically acclaimed series about a chess prodigy who gets “a little help from her friends.” In this episode we find out what they got right, and wrong, about psychiatric meds and cognitive enhancement. Published On: 1/11/2020 Duration: 29 minutes Transcript: Dr. Aiken: Cognitive problems are one


Rebuilding Life after Bipolar

January 4, 2021 | Podcasts

Brett Stevens has lived through the worst of bipolar and come out standing. Here’s what he did to get his life back. This is the first edition of The Pocket Psychiatrist, a monthly series you can share with your patients through a separate podcast stream. Published On: 1/4/2021 Duration: 15 minutes, 24 seconds Transcript: Last year, we put o



December 21, 2020 | Podcasts

Retractions are on the rise in medical research, and we get to the bottom of it with Ivan Oransky, cofounder of Published On: 12/21/2020 Duration: 25 minutes, 12 seconds Rough Transcript: Can you personalize antidepressant selection, use antipsychotics in dementia, or treat adolescent OCD with brain surgery? Yes, you can….


Ritalin, Provigil, and Caffeine Compared [60 Sec Psych]

December 2, 2020 | Podcasts

About 1 in 50 US adults use stimulants like amphetamines (Adderall), methylphenidate (Ritalin), and modafinil (Provigil) without a prescription, and 80% of them take the drugs to enhance cognition, not to get high. The ethics of all this are vexing, but putting that aside, how well does the practice work? And how does it compare to drug that most of


Reimagining ADHD with Edward Hallowell, MD

November 30, 2020 | Podcasts

While medication is the mainstay of treating symptoms in ADHD, Edward Hallowell, MD, shares a positive, relationship-based approach to ADHD with practical strategies to help children and adolescents manage ADHD. Published On: 11/30/2020 Duration: 18 minutes, 10 seconds Related Article: "Reimagining ADHD," The Carlat Child Psychiatry Report


A New Cause of ADHD [60 Sec Psych]

October 31, 2020 | Podcasts

Chemicals from plastics, pesticides, and food processing are linked to ADHD, according to a new paper in JAMA Open Network. [Link] Published On: 10/31/2020 Duration: 3 minutes, 1 second Got feedback? Take the podcast survey.


A New Medication for Narcolepsy [60 Sec Psych]

October 28, 2020 | Podcasts

Xyrem is a branded form of sodium oxybate, the sodium salt of gamma-hydroxybutyrate, or GHB , to precursor to GABA, glutamate, and glycine which is FDA approved for narcolepsy and cataplexy. The news on Xyrem is that the FDA just approved a new version of it – called Xywav – made by Jazz pharmaceuticals. [FDA Prescribing Information] Date Publis


How to use Guanfacine and Clonidine

October 26, 2020 | Podcasts

We take you through the story of rational drug discovery that lead to the approval of guanfacine and clonidine for ADHD, and share some tips on how to use them. And the word of the day: Dyssymbole. Published On: 10/26/2020 Duration: 19 minutes, 55 seconds Article Referenced: "Guanfacine ER for Adults With ADHD?" The Carlat Psychiatry Report


A Prescription Video Game for ADHD [60 Sec]

October 24, 2020 | Podcasts

The hand eye movements of a prescription video game are thought to exercise circuits involved in attention, and this theory did translate to small but real improvements in attention in 5 clinical trials involving over 600 children with ADHD Published On: 10/24/2020 Duration: 3 minutes, 4 seconds Transcript:  A spaceman rides down an icy


Two Updates on Pimavenserin [60 Sec Psych]

October 21, 2020 | Podcasts

Last April we reported on Pimavenserin – Nuplazid – the novel antipsychotic that’s FDA approved in psychosis related to parkinson’s disease. In that article we mentioned a randomized controlled trial from Mass General – the CLARITY trial - that showed promising augmentation effects when Pimavenserin was added to an antidepressant in major de